This is feed that updates daily with CME offerings from JAMA, American College of Surgeons, and UC CMEs. Please follow the links for each to learn more.
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA Oncology Read More
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA OncologyRead More
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA Oncology Read More
A Diffuse Medullary Hypercaptation With No Bone Lesion
CLINICAL CHALLENGE | 1 Credit | CME | A Diffuse Medullary Hypercaptation With No Bone Lesion | JAMA Oncology Read More
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA Oncology Read More
A Diffuse Medullary Hypercaptation With No Bone Lesion
CLINICAL CHALLENGE | 1 Credit | CME | A Diffuse Medullary Hypercaptation With No Bone Lesion | JAMA OncologyRead More
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA OncologyRead More
A Diffuse Medullary Hypercaptation With No Bone Lesion
CLINICAL CHALLENGE | 1 Credit | CME | A Diffuse Medullary Hypercaptation With No Bone Lesion | JAMA Oncology Read More
Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers
ONCOLOGY | 12m 23s | Cost Transparency for Prostate Cancer Radiation Therapy at National Cancer Institute–Designated Cancer Centers | JAMA Oncology Read More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA Oncology Read More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA OncologyRead More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA Oncology Read More
Progressive Dyspnea in a Woman With Genital Skin Lesions
CLINICAL CHALLENGE | 1 Credit | CME | Progressive Dyspnea in a Woman With Genital Skin Lesions | JAMA Oncology Read More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA Oncology Read More
Progressive Dyspnea in a Woman With Genital Skin Lesions
CLINICAL CHALLENGE | 1 Credit | CME | Progressive Dyspnea in a Woman With Genital Skin Lesions | JAMA OncologyRead More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA OncologyRead More
Progressive Dyspnea in a Woman With Genital Skin Lesions
CLINICAL CHALLENGE | 1 Credit | CME | Progressive Dyspnea in a Woman With Genital Skin Lesions | JAMA Oncology Read More
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
CANCER BIOMARKERS | 1 Credit | CME | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: | A Randomized Clinical Trial | JAMA Oncology Read More
A Translucent Nodule of the Nipple in an Elderly Male Patient
CLINICAL CHALLENGE | 1 Credit | CME | A Translucent Nodule of the Nipple in an Elderly Male Patient | JAMA Dermatology Read More
A Translucent Nodule of the Nipple in an Elderly Male Patient
CLINICAL CHALLENGE | 1 Credit | CME | A Translucent Nodule of the Nipple in an Elderly Male Patient | JAMA DermatologyRead More
